You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 17, 2025

Drug Price Trends for TELMISARTAN-AMLODIPINE


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for TELMISARTAN-AMLODIPINE

Average Pharmacy Cost for TELMISARTAN-AMLODIPINE

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
TELMISARTAN-AMLODIPINE 40-10 00378-1076-93 2.47234 EACH 2025-01-22
TELMISARTAN-AMLODIPINE 80-5 MG 00378-1077-93 2.62044 EACH 2025-01-22
TELMISARTAN-AMLODIPINE 40-5 MG 00378-1075-93 2.15556 EACH 2025-01-22
TELMISARTAN-AMLODIPINE 80-10 00378-1078-93 2.54514 EACH 2025-01-22
TELMISARTAN-AMLODIPINE 40-10 00378-1076-93 2.30156 EACH 2024-12-18
TELMISARTAN-AMLODIPINE 80-5 MG 00378-1077-93 2.73422 EACH 2024-12-18
TELMISARTAN-AMLODIPINE 40-5 MG 00378-1075-93 2.21925 EACH 2024-12-18
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Telmisartan-Amlodipine Market Analysis and Price Projections

Market Overview

The telmisartan-amlodipine market is a segment of the broader antihypertensive drug market, driven by the increasing prevalence of hypertension and cardiovascular diseases globally. This combination therapy, which includes an angiotensin II receptor blocker (telmisartan) and a calcium channel blocker (amlodipine), is widely prescribed for the management of high blood pressure.

Market Size and Growth

The global telmisartan market, which includes telmisartan-amlodipine combinations, was valued at approximately USD 3.57 billion in 2023. It is projected to grow at a compound annual growth rate (CAGR) of 3.4% to 5.6% during the forecast period from 2024 to 2032, reaching a market value of USD 5.83 billion by 2032[1][3][4].

Key Drivers

Increasing Prevalence of Hypertension

The rising prevalence of hypertension is a significant driver of the telmisartan-amlodipine market. Hypertension affects over 1.13 billion people globally, and this number is expected to increase due to lifestyle factors such as sedentary lifestyles, obesity, and high consumption of salt, sugar, and fat-rich diets[4].

Growing Healthcare Spending

Increased healthcare spending and awareness about hypertension treatment also fuel the demand for telmisartan-amlodipine. In the U.S., for example, the National Health Expenditure (NHE) is projected to continue growing, reflecting increased demand for healthcare services and pharmaceuticals[1].

Government Policies and Awareness

Favorable government policies for the prevention and control of hypertension, along with growing awareness about the effectiveness and safety of telmisartan, further drive market growth. For instance, the National Heart Foundation in Australia has outlined important statements to support better hypertension management, contributing to increased market growth[1][4].

Regional Analysis

North America

North America is expected to be the largest market for telmisartan-amlodipine, driven by a high number of hypertension patients, advanced healthcare facilities, and a well-developed network of hospital and online pharmacies. The region is projected to grow at a CAGR of 3.4% during the forecast period[1].

Asia Pacific

The Asia Pacific region is anticipated to be the fastest-growing market, with countries like China and India contributing significantly. This growth is driven by a large patient population, increasing healthcare expenditures, and favorable government policies promoting local manufacturing. The region is expected to grow at a CAGR of 5.5% during the forecast period[1][4].

Price Projections

Current Pricing

The cost for amlodipine/telmisartan oral tablets varies based on the dosage and pharmacy. For example, a supply of 30 tablets of amlodipine/telmisartan (10 mg-40 mg) can cost around $62.45, while a supply of 30 tablets of amlodipine/telmisartan (5 mg-80 mg) can cost around $112.09[2].

Future Pricing Trends

While the prices of branded pharmaceuticals are expected to remain relatively stable, the average selling price of telmisartan-amlodipine is likely to decline due to the increasing availability of generic substitutes. By 2020, around 60% of the global consumption of telmisartan was fulfilled by generic drug manufacturers, reflecting a shift towards more affordable healthcare options[4].

Market Challenges

Patent Expiration

The expiration of patents for major drugs, including telmisartan, has led to an increase in generic competition. This has resulted in a decline in the average selling price and impacted the profit margins of innovator companies[4].

Medication Shortages

Medication shortages are another challenge that could hinder the market expansion of telmisartan-amlodipine. These shortages can be due to various factors, including supply chain disruptions and regulatory issues[1].

Market Opportunities

Growing Demand for Generics

The increasing demand for generic drugs offers significant opportunities for companies in the telmisartan-amlodipine market. As healthcare costs continue to rise, more patients and governments are seeking affordable healthcare options, driving the expansion of the generic drug industry[4].

Combination Therapies

The rising demand for fixed-dose combination therapies, which offer enhanced efficacy and adherence, presents lucrative opportunities for market players. The approval of telmisartan for additional indications, such as diabetic kidney disease, further strengthens its clinical profile[4].

Clinical Efficacy and Safety

Telmisartan-amlodipine combination therapy is known for its effectiveness in lowering blood pressure and reducing the risk of cardiovascular events. Studies have shown that long-term use of telmisartan can lower the risk of stroke and dementia in elderly hypertensive patients, and it is superior to other ARBs in reducing cardiovascular and all-cause mortality[4].

"Telmisartan is an angiotensin receptor blocker (ARB) that is widely prescribed by cardiologists and vascular physicians for the management of high blood pressure. It is known to be well-tolerated with minimal side effects as compared to other anti-hypertensive drugs."[4]

Key Takeaways

  • The global telmisartan market, including telmisartan-amlodipine combinations, is expected to grow significantly due to the increasing prevalence of hypertension and cardiovascular diseases.
  • North America and the Asia Pacific region are key markets, driven by different factors such as advanced healthcare facilities and a large patient population, respectively.
  • The market is challenged by patent expirations and medication shortages but presents opportunities in the growing demand for generics and combination therapies.
  • Telmisartan-amlodipine combination therapy is clinically effective and safe, making it a preferred treatment option for hypertension.

FAQs

What is the current market size of the telmisartan market?

The global telmisartan market was valued at approximately USD 3.57 billion in 2023[1][3].

What is the projected growth rate of the telmisartan market?

The telmisartan market is expected to grow at a CAGR of 3.4% to 5.6% during the forecast period from 2024 to 2032[1][3][4].

Which region is expected to be the fastest-growing market for telmisartan-amlodipine?

The Asia Pacific region is anticipated to be the fastest-growing market, driven by a large patient population and increasing healthcare expenditures[1][4].

What are the key drivers of the telmisartan-amlodipine market?

Key drivers include the increasing prevalence of hypertension, growing healthcare spending, and favorable government policies for hypertension prevention and control[1][4].

How does the availability of generic substitutes impact the telmisartan-amlodipine market?

The availability of generic substitutes has led to a decline in the average selling price and impacted the profit margins of innovator companies, but it also presents opportunities for companies in the generic drug industry[4].

What are the clinical benefits of telmisartan-amlodipine combination therapy?

Telmisartan-amlodipine combination therapy is effective in lowering blood pressure and reducing the risk of cardiovascular events, with minimal side effects compared to other anti-hypertensive drugs[4].

Sources

  1. Straits Research: Telmisartan Market Size, Share and Forecast to 2030[1]
  2. Drugs.com: Amlodipine/telmisartan Prices, Coupons, Copay Cards & Patient Assistance[2]
  3. Expert Market Research: Telmisartan Market Size, Growth & Share Report | 2032[3]
  4. Coherent Market Insights: Telmisartan Market - Share, Size and Industry Analysis[4]

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.